# Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

> **NCT01425970** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 210 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** Placebo matching with INX-08189
- **BIOLOGICAL:** Pegylated interferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** INX-08189
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT01425970
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 210 (ACTUAL)
- **Why stopped:** Termination of study was due to safety reasons
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425970, "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01425970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*